SYRS - サイロス・ファ―マシュ―ティカルズ (Syros Pharmaceuticals Inc.) サイロス・ファ―マシュ―ティカルズ

 SYRSのチャート


 SYRSの企業情報

symbol SYRS
会社名 Syros Pharmaceuticals Inc (サイロス・ファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 医薬品   医療関連(Health Care)
概要 事業概要 シロス・ファーマーセウティカルズ(Syros Pharmaceuticals Inc.)はバイオ医薬品会社である。同社はヒト疾病組織における未知のデオキシリボ核酸(DNA)の領域を分析し、ゲノム的に定義された患者集団に関連する標的を同定し、薬物を創出するように設計された遺伝子制御プラットフォームを提供する。同社はがんおよび免疫媒介疾患の治療法の開発に注力し、遺伝子制御薬のパイプラインを構築している。同社の薬物プログラムには、SY-1425(レチノイン酸受容体アルファ(RARa)アゴニスト)およびSY-1365(サイクリン依存性キナーゼ7(CDK7)阻害剤)が含まれる。SY-1425(タミバロチン)は、転写因子RARaの経口の強力で選択的なアゴニストまたは活性化剤である。SY-1365は、CDK7として知られた転写キナーゼの小分子阻害剤である。同社はそのプラットフォームを使用して、追加の癌、炎症性疾患および他の疾患にわたって遺伝子発現プログラムを分析し、患者の特定のサブセットにおける治療的介入の最適点を同定する。   サイロス・ファ―マシュ―ティカルズは米国のバイオ医薬品企業。主として、遺伝子の起動や抑制をコントロ―ルするゲノム制御分野に基づき、ガンや免疫性疾患の治療薬の開発、製造を行う。同社の遺伝子制御プラットフォ―ムは、ゲノム的定義に関連した新たな遺伝子制御の特定や遺伝子制御を麻痺させることを目的とする。本社はマサチュ―セッツ州ケンブリッジ。   Syros is redefining the power of small molecules to control the expression of genes. Based on its unique ability to elucidate regulatory regions of the genome, Syros aims to develop medicines that provide a profound benefit for patients with diseases that have eluded other genomics-based approaches. Syros is advancing a robust clinical-stage pipeline, including: SY-1425, a first-in-class oral selective RARα agonist in RARA-positive patients with higher-risk myelodysplastic syndrome and acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide in patients with acute promyelocytic leukemia; and SY-5609, a highly selective and potent oral CDK7 inhibitor in patients with select solid tumors. Syros also has multiple preclinical and discovery programs in oncology and monogenic diseases.
本社所在地 620 Memorial Drive Suite 300 Cambridge MA 02139 USA
代表者氏名 Peter Wirth ピーター・ワース
代表者役職名 Independent Chairman of the Board
電話番号 +1 617-744-1340
設立年月日 40848
市場名 NASDAQ National Market System
ipoyear 2016年
従業員数 56人
url www.syros.com
nasdaq_url https://www.nasdaq.com/symbol/syrs
adr_tso
EBITDA EBITDA(百万ドル) -57.38400
終値(lastsale) 8.26
時価総額(marketcap) 277985253.14
時価総額 時価総額(百万ドル) 239.28270
売上高 売上高(百万ドル) 0.74500
企業価値(EV) 企業価値(EV)(百万ドル) 114.95270
当期純利益 当期純利益(百万ドル) -57.63700
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Syros Pharmaceuticals Inc revenues decreased 32% to $745K. Net loss increased 15% to $28.5M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research_Development - Balancing value increase of 11% to $21M (expense) Stock-based Compensation in SGA increase of 75% to $2.2M (expense).

 SYRSのテクニカル分析


 SYRSのニュース

   Syros rises 13% as tamibarotene gets FDA orphan drug status for myelodysplastic syndrome  2022/02/02 21:09:08 Seeking Alpha
The U.S. Food and Drug Administration granted orphan drug designation to Syros Pharmaceuticals'' (SYRS) tamibarotene to treat myelodysplastic syndrome ((MDS)).Tamibarotene is
   Syros Pharmaceuticals Inc. Shares Close the Week 26.0% Lower - Weekly Wrap  2022/01/19 18:40:39 Kwhen Finance
Syros Pharmaceuticals Inc. (SYRS) shares closed this week 26.0% lower than it did at the end of last week. The stock is currently down 25.8% year-to-date, down 82.8% over the past 12 months, and down 79.3% over the past five years. This week, the Dow Jones Industrial Average fell 2.4%, and the S&P 500 fell 2.8%. Trading Activity Shares traded as high as $3.38 and as low as $2.40 this week.Trading volume this week was 4.7% lower than the 10-day average and 13.0% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.7. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price lags the S&P 500 Index this week, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price lags the Dow Jones Industrial Average this week, lags it on a 1-year basis, and lags it on a 5-year basis The company share price lags the performance of its peers in the Health Care industry sector this week, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 328.5% The company's stock price performance over the past 12 months lags the peer average by 156.8% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   Syros Pharmaceuticals Inc. Shares Approach 52-Week Low - Market Mover  2022/01/12 10:41:25 Kwhen Finance
Syros Pharmaceuticals Inc. (SYRS) shares closed today at 1.9% above its 52 week low of $3.21, giving the company a market cap of $202M. The stock is currently up 0.3% year-to-date, down 72.9% over the past 12 months, and down 72.5% over the past five years. This week, the Dow Jones Industrial Average fell 1.3%, and the S&P 500 fell 2.6%. Trading Activity Trading volume this week was 18.8% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.4. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -117.0% The company's stock price performance over the past 12 months lags the peer average by 140.8% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   Syros Pharmaceuticals Inc. Shares Near 52-Week Low - Market Mover  2021/12/30 02:58:22 Kwhen Finance
Syros Pharmaceuticals Inc. (SYRS) shares closed today at 1.5% above its 52 week low of $3.30, giving the company a market cap of $214M. The stock is currently down 68.0% year-to-date, down 71.5% over the past 12 months, and down 72.2% over the past five years. This week, the Dow Jones Industrial Average rose 2.6%, and the S&P 500 rose 3.0%. Trading Activity Trading volume this week was 10.0% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.5. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 125.3% The company's stock price performance over the past 12 months lags the peer average by 129.1% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   -$0.44 Earnings Per Share Expected for Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) This Quarter  2021/12/09 11:32:42 Dakota Financial News
Equities analysts predict that Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) will announce earnings per share (EPS) of ($0.44) for the current fiscal quarter, Zacks Investment Research reports. Five analysts have provided estimates for Syros Pharmaceuticals earnings, with estimates ranging from ($0.48) to ($0.38). Syros Pharmaceuticals reported earnings of ($0.61) per share in the same quarter last year, []
   -$0.44 EPS Expected for Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) This Quarter  2021/12/06 18:18:42 Transcript Daily
Analysts forecast that Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) will post earnings of ($0.44) per share for the current fiscal quarter, according to Zacks. Five analysts have made estimates for Syros Pharmaceuticals earnings, with the highest EPS estimate coming in at ($0.38) and the lowest estimate coming in at ($0.48). Syros Pharmaceuticals posted earnings per share of []
   Syros Pharmaceuticals Inc. (SYRS): Significant Improvements, Worth Being Considered  2021/12/04 16:00:00 Stocks Register
Syros Pharmaceuticals Inc. (NASDAQ:SYRS) concluded the trading at $3.55 on Friday, December 03 with a fall of -7.07% from its closing price on previous day. Taking a look at stock we notice that its last check on previous day was $3.82 and 5Y monthly beta was reading 1.88. Considering stocks 52-week price range provides that Syros Pharmaceuticals Inc. (SYRS): Significant Improvements, Worth Being Considered Read More »
   Nuveen Asset Management LLC Raises Stock Position in Syros Pharmaceuticals, Inc. (NASDAQ:SYRS)  2021/11/29 09:28:44 Dakota Financial News
Nuveen Asset Management LLC increased its holdings in shares of Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) by 23.1% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 180,514 shares of the companys stock after purchasing an additional 33,901 shares during the []
   Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Expected to Post Quarterly Sales of $5.65 Million  2021/11/26 01:12:41 Dakota Financial News
Brokerages expect Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) to post $5.65 million in sales for the current quarter, according to Zacks. Five analysts have provided estimates for Syros Pharmaceuticals earnings. The highest sales estimate is $6.00 million and the lowest is $5.00 million. Syros Pharmaceuticals posted sales of $5.70 million in the same quarter last year, which []
   Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Shares Bought by Northern Trust Corp  2021/11/24 09:20:45 Dakota Financial News
Northern Trust Corp raised its stake in Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) by 6.6% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 554,422 shares of the companys stock after purchasing an additional 34,517 shares during the quarter. Northern Trust Corp owned []
   Global Blood Therapeutics Consensus Indicates Potential 176.4% Upside  2021/09/29 12:01:29 DirectorsTalk
Global Blood Therapeutics found using ticker (GBT) have now 19 analysts in total covering the stock. The consensus rating is ''Buy''. The range between the high target price and low target price is between 138 and 30 with a mean TP of 72.47. With the stocks previous close at 26.22 this indicates there is a potential upside of 176.4%. The 50 day MA is 28.03 and the 200 day MA is 35.13. The company has a market capitalisation of $1,657m. Company Website: /> [stock_market_widget type="chart" symbol="GBT" chart="bar" range="6mo" interval="1d" line-color="rgb(49, 125, 189)"] Global Blood Therapeutics, a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. The company offers Oxbryta tablets, an oral, once-daily therapy for sickle cell disease (SCD). It is evaluating the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase 2a clinical trial of adolescent and pediatric patients with SCD. In addition, the company is developing inclacumab, a novel human monoclonal antibody to treat vaso-occlusive crises; and GBT601, a hemoglobin polymerization inhibitor.
   Syros Reports Inducement Grant to Chief Commercial Officer under Nasdaq Listing Rule 5635(c)(4)  2021/09/28 20:01:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (Nasdaq: SYRS) ("Syros" or the "Company"), a leader in the development of medicines that control the expression of genes, today announced the grant of an inducement stock option award to Conley Chee, the Company’s recently hired Chief Commercial Officer, in accordance with Mr. Chee’s employment offer letter. The grant was approved by the Company’s Board of Directors and was made as a material inducement to Mr. Chee’s acceptance of employm
   Syros Pharmaceuticals (SYRS) Investor Presentation  2021/09/27 21:00:46 Seeking Alpha
   Syros Announces Appointment of Conley Chee as Chief Commercial Officer  2021/09/27 12:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced the appointment of Conley Chee as the companys first Chief Commercial Officer. Mr. Chee brings 20 years of pharmaceutical sales leadership, marketing and strategy experience in the U.S. and globally, with particular expertise in driving commercial strategy for novel medicines for the treatment of cancer. We are pleased to welcom
   Mind-blowing stocks: Worksport Ltd. (NASDAQ:WKSP -7.77%), Syros Pharmaceuticals, Inc. (NASDAQ:SYRS 2.04%)  2021/09/24 00:01:27 Stock Equity
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 The post Mind-blowing stocks: Worksport Ltd. (NASDAQ:WKSP -7.77%), Syros Pharmaceuticals, Inc. (NASDAQ:SYRS 2.04%) appeared first on Stocks Equity .

 関連キーワード  (医薬品 米国株 サイロス・ファ―マシュ―ティカルズ SYRS Syros Pharmaceuticals Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)